Skip to main content

Table 1 Antibody titers and protection

From: Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice

Sample (dilution) HI GMT MN GMT % survival
In vitroa In vivo In vitroa In vivo
  Day 3b Day 32c   Day 3b Day 32c
H-IVIG (undiluted) 1280 163 33 3420 349 34 100
H-IVIG (1:2) 640 143 26 1710 190 15 95
H-IVIG (1:4) 320 63 14 855 95 11 90
H-IVIG (1:8) 160 35 8 428 48 6 76
H-IVIG (1:16) 80 21 6 214 24 5 63
IVIG (undiluted) 70 6 7 60 5 5 50
Buffer control n.a. 5 5 n.a. 5 5 40
  1. ain vitro titer of neat samples determined prior to i.p. injection; titers of diluted H-IVIG are calculated accordingly.
  2. bmouse serum titers 3 days after passive transfer; i.e. at the time of challenge.
  3. cmouse serum titers 32 days after passive transfer; i.e. 29 days after challenge.
  4. HI, hemagglutination inhibition; MN, microneutralization; GMT, geometric mean titer; n.a., not applicable.
  5. Note: IVIG was a pooled preparation from 5 different IVIG lots; 2 different lots of H-IVIG were used separately. Data shown are combined data from 2 independent experiments.